Analysis of the key themes driving M&A activity reveals that orphan designated drugs accounted for 28 pharmaceutical deals announced in Q2 2023, worth a total value of $9.7bn. The $3.5bn acquisition of Chinook Therapeutics by Novartis was the industry’s largest disclosed deal. GlobalData’s Pharmaceuticals Industry Mergers and Acquisitions Deals by Top Themes report for Q2 2023 dissects the driving forces behind the M&A dynamics within the Pharma sector, offering essential insights into industry trends and transformations. Buy the report here.
In value terms, orphan designated drugs-related deal activity decreased by 81% in Q2 2023 compared with the previous quarter’s total of $50.5bn and fell by 49% as compared to Q2 2022. Related deal volume increased by 17% in Q2 2023 versus the previous quarter and was 56% higher than in Q2 2022.
The top-ranked financial advisors supporting these M&A deals in Q2 2023 were Centerview Partners; Guggenheim Partners; MTS Health Partners with 8, 3, 3 deals respectively.
The top-ranked legal advisors supporting these M&A deals in Q2 2023 were Gibson, Dunn & Crutcher; Cooley; Goodwin Procter with 7, 5, 5 deals respectively.
For further understanding of GlobalData's Pharmaceuticals Industry M&A Deals by Top Themes in Q2 2023 – Thematic Intelligence, buy the report here.